diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM9630diaendo-9630Research ArticleОригинальные исследованияOriginal StudiesВлияние омега-3 полиненасыщенных жирных кислот на параметры амбулаторного мониторинга артериального давления у пациентов с сахарным диабетом 2 типа и автономной невропатией сердцаThe effect of OMEGA-3 polyunsaturated fatty acids on ambulatory blood pressure monitoring parameters in patients with type 2 diabetes mellitus and cardiovascular autonomic neuropathyhttps://orcid.org/0000-0002-6414-0956СергиенкоВиктория АлександровнаSerhiyenkoVictoria A.

д.м.н., доцент

MD, PhD

serhiyenkov@gmail.comhttps://orcid.org/0000-0001-8289-3604МаньковскийБорис НикитичMankovskyBoris N.

д.м.н., профессор, член-корреспондент НАМН Украины

MD, PhD, Professor

mankovsky1964@yahoo.comhttps://orcid.org/0000-0001-9873-9847СергиенкоЛюдмила МихайловнаSerhiyenkoLudmila М.

к.б.н., доцент

MD, PhD

serhiyenkoludmila@gmail.comhttps://orcid.org/0000-0002-3905-0326СергиенкоАлександр АлексеевичSerhiyenkoAleksandr A.

д.м.н., профессор

MD, PhD, Professor

serhiyenkoa@gmail.com<p>Львовский национальный медицинский университет им. Данила Галицкого</p>Украина<p>Danylo Halitsky National Medical University</p>Ukraine<p>Национальная медицинская академия последипломного образования им. П.Л. Шупика</p>Украина<p>P.L. Shupik National Medical Academy of Postgraduate Education</p>Ukraine2019080420192216269Copyright &#x00A9; Сергиенко В.А., Маньковский Б.Н., Сергиенко Л.М., Сергиенко А.А., 20192019Сергиенко В.А., Маньковский Б.Н., Сергиенко Л.М., Сергиенко А.А.Serhiyenko V.A., Mankovsky B.N., Serhiyenko L.М., Serhiyenko A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/9630Обоснование

Обоснование. Диабетическая автономная невропатия сердца (ДАНС) при сахарном диабете 2 типа (СД2) характеризуется поражением нервных волокон парасимпатической и симпатической нервной системы, является одной из ведущих причин сердечных аритмий и независимым фактором риска сердечно-сосудистой смертности у пациентов с СД2. Поэтому проблема эффективного лечения ДАНС особенно актуальна.

Цель

Цель. Проанализировать влияние длинноцепочечных полиненасыщенных жирных кислот (ω-3 ПНЖК) на параметры амбулаторного мониторинга артериального давления у пациентов c СД2 и ДАНС.

Методы

Методы. 36 пациентов c СД2 и подтвержденной ДАНС были разделены на 2 группы. Первая группа получала гипо гликемическую терапию (n=15, контроль) в течение 3 мес; пациентам второй группы (n=21) дополнительно назначали 1 капсулу/сут препарата ω-3 ПНЖК в течение 3 мес.

Результаты

Результаты. Использование ω-3 ПНЖК сопровождалось значительным снижением диастолического артериального давления (ДАД) (p<0,01), индекса площади гипертонии ДАД (p<0,05), индекса времени гипертонии ДАД (p<0,05) в течение дня; ДАД (p<0,05), индекса площади гипертонии ДАД (p<0,05), индекса времени гипертонии ДАД (p<0,05), стандартного отклонения ДАД (p<0,01)] в ночные часы (по сравнению с контрольной группой).

Заключение

Заключение. Полученные результаты свидетельствуют, что назначение ω-3 ПНЖК на протяжении 3 мес эффективно влияет на снижение параметров ДАД у больных СД2 и ДАНС.

Background

Background: Cardiovascular autonomic neuropathy (CAN) in type 2 diabetes mellitus (T2DM), which is characterized by lesion of nerve fibers in parasympathetic and sympathetic nervous system is one of the leading causes of heart arrhythmias and an independent risk factor for cardiovascular mortality in patients with T2DM. Therefore, the problem of effective treatment of CAN is particularly relevant.

Aims

Aims: To analyze the effect of long-chain polyunsaturated fatty acids (ω-3 PUFAs) on ambulatory blood pressure monitoring parameters in patients with T2DM and CAN.

Materials and methods

Materials and methods: 36 patients with T2DM and confirmed CAN were divided into two groups. First group received hypoglycemic therapy (n=15, control) for three months; patients in group 2 (n=21) in addition were administered 1 capsule/q.d. of ω-3 PUFAs for three month.

Results

Results: Treatment with ω-3 PUFAs led to significant decrease of the diastolic blood pressure (DBP) (p<0,01), diastolic blood pressure load (p<0,05), time index of DBP (p<0,05) during the day; DBP (p<0,05), diastolic blood pressure load (p<0,05), time index of DBP (p<0,05), SD DBP (p<0,01) during the night (compared to the control group).

Conclusions

Conclusions: The study showed that prescription of ω-3 PUFAs for three month was effective in decreasing diastolic blood pressure and its parameters among patients with T2DM and CAN.

диабетическая кардиоваскулярная автономная нейропатияполиненасыщенные жирные кислотымониторинг артериального давленияdiabetic cardiovascular autonomic neuropathypolyunsaturated fatty acidsambulatory blood pressure monitoringReferencesОсложнения сахарного диабета: лечение и профилактика. / Под. ред. Дедова И.И., Шестаковой М.В. — М.: Московское информационное агентство; 2017. [Dedov II, Shestakova MV, editors. Complications of diabetes mellitus: treatment and prophylactic. Moscow: Moskovskoe informatsionnoe agentstvo; 2017. (In Russ.)]Осложнения сахарного диабета: лечение и профилактика. / Под. ред. Дедова И.И., Шестаковой М.В. — М.: Московское информационное агентство; 2017. [Dedov II, Shestakova MV, editors. Complications of diabetes mellitus: treatment and prophylactic. Moscow: Moskovskoe informatsionnoe agentstvo; 2017. (In Russ.)]Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747-787. doi: 10.1016/j.ecl.2013.06.001Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747-787. doi: 10.1016/j.ecl.2013.06.001Balcioglu AS, Muderrisoglu H. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015;6(1):80-91. doi: 10.4239/wjd.v6.i1.80Balcioglu AS, Muderrisoglu H. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015;6(1):80-91. doi: 10.4239/wjd.v6.i1.80Ziegler D, Keller J, Maier C, et al. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2014;122(7):406-415. doi: 10.1055/s-0034-1366435Ziegler D, Keller J, Maier C, et al. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2014;122(7):406-415. doi: 10.1055/s-0034-1366435Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi: 10.2337/dc16-2042Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi: 10.2337/dc16-2042Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639-653. doi: 10.1002/dmrr.1239Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639-653. doi: 10.1002/dmrr.1239Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Omega-3 polyunsaturated fatty acids in the treatment of diabetic cardiovascular autonomic neuropathy: A review. In: Moore SJ, editor. Omega-3: Dietary sources, biochemistry and impact on human health. New York: Nova Science Publishers; 2017.Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Omega-3 polyunsaturated fatty acids in the treatment of diabetic cardiovascular autonomic neuropathy: A review. In: Moore SJ, editor. Omega-3: Dietary sources, biochemistry and impact on human health. New York: Nova Science Publishers; 2017.Townsend RR, Wilkinson IB, Schiffrin EL, et al. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015;66(3):698-722. doi: 10.1161/HYP.0000000000000033Townsend RR, Wilkinson IB, Schiffrin EL, et al. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015;66(3):698-722. doi: 10.1161/HYP.0000000000000033Colussi G, Catena C, Novello M, et al. Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: Relevance for cardiovascular outcomes. Nutr Metab Cardiovasc Dis. 2017;27(3):191-200. doi: 10.1016/j.numecd.2016.07.011Colussi G, Catena C, Novello M, et al. Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: Relevance for cardiovascular outcomes. Nutr Metab Cardiovasc Dis. 2017;27(3):191-200. doi: 10.1016/j.numecd.2016.07.011Koumaras C, Katsiki N, Athyros VG, Karagiannis A. Metabolic syndrome and arterial stiffness: the past, the present and the future. J Cardiovasc Med (Hagerstown). 2013;14(10):687-689. doi: 10.2459/JCM.0b013e3283657c96Koumaras C, Katsiki N, Athyros VG, Karagiannis A. Metabolic syndrome and arterial stiffness: the past, the present and the future. J Cardiovasc Med (Hagerstown). 2013;14(10):687-689. doi: 10.2459/JCM.0b013e3283657c96Pase MP, Grima N, Cockerell R, et al. The effects of long-chain omega-3 fish oils and multivitamins on cognitive and cardiovascular function: a randomized, controlled clinical trial. J Am Coll Nutr. 2015;34(1):21-31. doi: 10.1080/07315724.2014.880660Pase MP, Grima N, Cockerell R, et al. The effects of long-chain omega-3 fish oils and multivitamins on cognitive and cardiovascular function: a randomized, controlled clinical trial. J Am Coll Nutr. 2015;34(1):21-31. doi: 10.1080/07315724.2014.880660Harris WS, Del Gobbo L, Tintle NL. The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. Atherosclerosis. 2017;262:51-54. doi: 10.1016/j.atherosclerosis.2017.05.007Harris WS, Del Gobbo L, Tintle NL. The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. Atherosclerosis. 2017;262:51-54. doi: 10.1016/j.atherosclerosis.2017.05.007Arteriograph.nl [Internet]. Arteriograph and TensioMed™ program. Available from: http://www.arteriograph.nl/.Arteriograph.nl [Internet]. Arteriograph and TensioMed™ program. Available from: http://www.arteriograph.nl/.Hermida R, Smolensky MH, Ayala DE, et al. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30(3):355-410. doi: 10.3109/07420528.2013.750490Hermida R, Smolensky MH, Ayala DE, et al. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30(3):355-410. doi: 10.3109/07420528.2013.750490Mahabala C, Kamath P, Bhaskaran U, et al. Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently? Vasc Health Risk Manag. 2013;9:125-133. doi: 10.2147/VHRM.S33515Mahabala C, Kamath P, Bhaskaran U, et al. Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently? Vasc Health Risk Manag. 2013;9:125-133. doi: 10.2147/VHRM.S33515Kiecolt-Glaser JK, Epel ES, Belury MA, et al. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. Brain Behav Immun. 2013;28:16-24. doi: 10.1016/j.bbi.2012.09.004Kiecolt-Glaser JK, Epel ES, Belury MA, et al. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. Brain Behav Immun. 2013;28:16-24. doi: 10.1016/j.bbi.2012.09.004Mansour AS, Yannoutsos A, Majahalme N, et al. Aortic stiffness and cardiovascular risk in type 2 diabetes. J Hypertens. 2013;31(8):1584-1592. doi: 10.1097/HJH.0b013e3283613074Mansour AS, Yannoutsos A, Majahalme N, et al. Aortic stiffness and cardiovascular risk in type 2 diabetes. J Hypertens. 2013;31(8):1584-1592. doi: 10.1097/HJH.0b013e3283613074Campbell F, Dickinson HO, Critchley JA, et al. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013;20(1):107-120. doi: 10.1177/2047487312437056Campbell F, Dickinson HO, Critchley JA, et al. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013;20(1):107-120. doi: 10.1177/2047487312437056Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018;9(1):1-24. doi: 10.4239/wjd.v9.i1.1Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018;9(1):1-24. doi: 10.4239/wjd.v9.i1.1

The authors declare that there are no conflicts of interest present.